Disclosed is a use of a RASIP1 modulator in the manufacture of a medicament for treating a disorder associated with altered vascular barrier function in a subject wherein the disorder is selected from the group consisting of sepsis, age-related macular degeneration (AMD), edema, ischemic stroke, hemorrhage, and hypertension. Also disclosed is a use of a RASIP1 agonist in the manufacture of a medicament for treating cancer or a proliferative retinopathy.